Skip Navigation



Annals of Oncology Advance Access published online on July 12, 2005
Annals of Oncology, doi:10.1093/annonc/mdi279
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/9/1425    most recent
mdi279v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Segaert, S.
Right arrow Articles by Van Cutsem, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segaert, S.
Right arrow Articles by Van Cutsem, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received February 3, 2005
Revised May 3, 2005
Accepted May 3, 2005

Review

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

S. Segaert 1 and E. Van Cutsem 2*

1 Department of Dermatology, University Hospital, Katholieke Universiteit Leuven, Belgium
2 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium

* To whom correspondence should be addressed.
E. Van Cutsem, E-mail: Eric.VanCutsem{at}uz.kuleuven.ac.be


  Abstract

The last few years, new therapies targeting the epidermal growth factor receptor (EGFR) have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies against the EGFR (e.g. cetuximab, panitumumab) or EGFR tyrosine kinase inhibitors (e.g. gefitinib, erlotinib) are generally well tolerated and do not have the severe systemic side-effects usually seen with cytotoxic drugs. A considerable number of patients treated with these EGFR inhibitors, however, develop dermatological side-effects, most frequently an acneiform eruption but also xerosis, eczema, fissures, telangiectasia, hyperpigmentation, hair changes and paronychia with pyogenic granuloma. These skin effects appear to be mechanism-based linked to the inhibition of EGFR action but the exact pathophysiology remains elusive. Left untreated these dermatological side-effects could represent a threat to patient compliance. Therefore effective management is mandatory. Mild cases of acneiform eruption respond well to topical anti-inflammatory acne therapy, whereas tetracyclines are needed to treat moderate to severe cases. This review outlines the broad spectrum of cutaneous side-effects of EGFR inhibitors, discusses possible underlying mechanisms and provides practical guidelines for the management based on literature data and on personal experience.

Keywords: acneiform eruption; cetuximab; epidermal growth factor receptor; erlotinib; gefitinib.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
E. H. Tan and A. Chan
Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
Ann. Pharmacother., October 1, 2009; 43(10): 1658 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Surguladze, D. Deevi, N. Claros, E. Corcoran, S. Wang, M. J. Plym, Y. Wu, J. Doody, D. J. Mauro, L. Witte, et al.
Tumor Necrosis Factor-{alpha} and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Cancer Res., July 15, 2009; 69(14): 5643 - 5647.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
V. Sans, T. Jouary, T. Hubiche, D. Smith, B. Milpied, and A. Taieb
Baboon Syndrome Induced by Cetuximab
Arch Dermatol, February 1, 2008; 144(2): 272 - 274.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bernier, J Bonner, J. B. Vermorken, R.-J. Bensadoun, R. Dummer, J. Giralt, G. Kornek, A. Hartley, R. Mesia, C. Robert, et al.
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
Ann. Onc., January 1, 2008; 19(1): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. R. Tan, S. M. Steinberg, A. L. Parr, D. Nguyen, and S. X. Yang
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment
Ann. Onc., January 1, 2008; 19(1): 185 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al.
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 215 - 223.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Scope, A. L. C. Agero, S. W. Dusza, P. L. Myskowski, J. A. Lieb, L. Saltz, N. E. Kemeny, and A. C. Halpern
Randomized Double-Blind Trial of Prophylactic Oral Minocycline and Topical Tazarotene for Cetuximab-Associated Acne-Like Eruption
J. Clin. Oncol., December 1, 2007; 25(34): 5390 - 5396.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Oncologist, December 1, 2007; 12(12): 1443 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Boeck, A Wollenberg, and V Heinemann
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib
Ann. Onc., September 1, 2007; 18(9): 1582 - 1583.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
J. E. Bauman, K. D. Eaton, and R. G. Martins
Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab
Arch Dermatol, July 1, 2007; 143(7): 889 - 892.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, C. Verslype, and P. A. Grusenmeyer
Lessons Learned in the Management of Advanced Pancreatic Cancer
J. Clin. Oncol., May 20, 2007; 25(15): 1949 - 1952.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture
Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
Oncologist, May 1, 2007; 12(5): 610 - 621.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. E Saadeh and H S. Lee
Panitumumab: A Fully Human Monoclonal Antibody with Activity in Metastatic Colorectal Cancer
Ann. Pharmacother., April 1, 2007; 41(4): 606 - 613.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K.-Y. Tsai, C.-H. Yang, T.-t. Kuo, H.-S. Hong, and J. W.C. Chang
Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma
J. Clin. Oncol., December 20, 2006; 24(36): 5786 - 5788.
[Full Text] [PDF]

Home page
 The OncologistHome page
E. Van Cutsem
Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 1010 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
W. A. High
Gefitinib: a cause of pyogenic granulomalike lesions of the nail.
Arch Dermatol, July 1, 2006; 142(7): 939 - 939.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.